TabletsClinical Overview
Clomiphene Citrate Tablets IP 50 mg is a non-steroidal selective estrogen receptor modulator (SERM) and first-line ovulatory stimulant on the WHO Model List of Essential Medicines. It antagonizes hypothalamic and pituitary estrogen receptors, blocking negative feedback of endogenous circulating estrogens; this triggers an increase in GnRH pulse frequency and endogenous FSH and LH secretion, stimulating ovarian follicular recruitment and maturation. Indicated for the treatment of ovulatory failure and female anovulatory infertility in women desiring pregnancy, predominantly in polycystic ovary syndrome (PCOS, WHO Group II anovulation).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 50 mg once daily with water for 5 consecutive days, starting on Day 2, 3, or 5 of the spontaneous or progestin-induced menstrual cycle. Ovulation typically occurs 5 to 10 days after the last tablet. If ovulation fails to occur, dose may be escalated in the subsequent cycle to 100 mg daily for 5 days under transvaginal ultrasound folliculometry. Maximum recommended treatment duration is 6 ovulatory cycles.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Vasomotor flushes (hot flashes), abdominal/pelvic bloating, breast tenderness, ovarian enlargement, nausea, headache, mood swings, and visual blurring (scotomas/spots). Rare/Severe: Ovarian Hyperstimulation Syndrome (OHSS), multiple gestation (twin pregnancy in ~8-10%), ovarian cyst torsion, and retinal vascular disturbances.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Discontinue immediately if visual disturbances occur. Contraindicated in established pregnancy, uncontrolled thyroid or adrenal dysfunction, liver disease, abnormal uterine bleeding of undetermined origin, ovarian cysts not due to PCOS, and hormone-dependent neoplasms. Baseline pelvic ultrasound recommended.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Gynecological, Obstetric & Endocrinological Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice or reproductive healthcare guidance. Hormonal medications, uterotonics, corticosteroids, fertility therapies, and emergency contraceptives have profound systemic actions and must be administered strictly under the supervision of a registered gynecologist, obstetrician, or endocrinologist.